NASDAQ$KYMR

Kymera Therapeutics Inc · Q2 2020 earnings

Q2 2020 earnings · · Investor relations

Headline financials

Total Revenue

$3.29M

No prior period
EPS (adj)

-$0.32

No prior period
Net Income

-$14M

No prior period
Operating Income

-$14.2M

No prior period
Gross Profit

$3.29M

No prior period
R&D Expense

$13.8M

No prior period

Revenue & EPS history

Kymera Therapeutics · Revenue · Quarterly

$3.29M

Q2 2020
Beat estimate in 5 of 11 quarters(45%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports

Historical avg

+1.0%

Avg return

Earnings day

+0.5%

Avg return

5 days after

+1.3%

Avg return

30 days after

55%

12 / 22 earnings

Positive

+23.5%

Q3 2023

Best reaction

-32.7%

Q1 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-0.5%+1.5%-0.2%
Q4 2025+4.8%-4.8%-13.8%
Q3 2025+0.3%-1.8%+10.9%
Q1 2025-2.0%-3.3%+54.8%
Q4 2024-14.5%-13.2%-16.2%
Q3 2024-2.5%+0.0%-1.7%
Q2 2024+1.4%+2.6%+9.6%
Q1 2024+3.2%+6.1%-11.4%
Q4 2023+8.2%+12.7%+5.3%
Q3 2023+23.5%+41.6%+79.8%
Q2 2023+5.0%-7.4%-7.6%
Q1 2023-6.1%-10.3%-12.5%
Q4 2022-0.2%-0.5%-7.0%
Q3 2022+7.3%+5.5%+7.1%
Q2 2022+8.3%+7.4%-8.5%
Q1 2022-32.7%-41.8%-55.3%
Q4 2021+11.4%+7.1%+12.4%
Q3 2021-3.6%-6.5%-19.1%
Q2 2021-3.3%-8.9%-3.6%
Q1 2021+6.8%+9.1%+15.7%
Q4 2020-2.2%+2.3%-41.7%
Q3 2020+8.7%+14.6%+32.2%
Q2 2020
Q1 2020
Q4 2019
Q3 2019

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro